Caxton Corp.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Caxton Corp. reported 15 stock positions worth $16.6 million. Its top holding was Xeris Biopharma (XERS) at 41.1% of the portfolio, followed by Rezolute (RZLT, 38.8%) and SS SPDR S&P 500 ETF Trust-US (SPY, 9.9%). Compared with Q3 2024, it opened 4 new positions, sold out of 1 and reduced 3. The biggest buy was a new position in SPDR Gold Shares (GLD) and the biggest sale Xeris Biopharma (XERS, shares −61%).
- Most Recent 13F
- Q2 2026
- Location
- Princeton, NJ
- CIK
- 0001388551
- Portfolio Value
- $16.6M (Q4 2024)
- SEC Filing
- 0000919574-25-001439 ↗ filed Feb 14, 2025
Holdings Value
Holdings 15 stocks · $16.6M
| XERS Xeris Biopharma Holdings Inc. | 41.06% | 2,015,157 | $6.8M | Reduce -60.6% |
| RZLT Rezolute Inc. | 38.85% | 1,318,967 | $6.5M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 9.94% | 2,823 | $1.7M | Reduce -1.5% |
| BRK.B Berkshire Hathaway Inc. Class B | 3.09% | 1,133 | $514K | Reduce -1.6% |
| GLD SPDR Gold Shares | 1.70% | 1,169 | $283K | New |
| MIND MEDICINE MINDMED INC | 1.43% | 34,073 | $237K | No change |
| BCAX Bicara Therapeutics Inc. | 1.15% | 10,941 | $191K | No change |
| LXEO Lexeo Therapeutics Inc. | 0.71% | 17,851 | $117K | No change |
| KYTX Kyverna Therapeutics Inc. | 0.52% | 22,981 | $86K | No change |
| CMPX Compass Therapeutics Inc. | 0.38% | 43,465 | $63K | No change |
| CRDF Cardiff Oncology Inc. | 0.35% | 13,287 | $58K | New |
| IKT Inhibikase Therapeutics Inc. | 0.32% | 16,393 | $53K | New |
| GLYCOMIMETICS INC | 0.31% | 203,578 | $51K | New |
| CNTX Context Therapeutics Inc. | 0.12% | 18,403 | $19K | No change |
| ACET Adicet Bio Inc. | 0.10% | 17,488 | $17K | No change |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
| GLD SPDR Gold Shares | New | 1.70% | +1.70 |
| CRDF Cardiff Oncology Inc. | New | 0.35% | +0.35 |
| IKT Inhibikase Therapeutics Inc. | New | 0.32% | +0.32 |
| GLYCOMIMETICS INC | New | 0.31% | +0.31 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $1.9M | SPCX, BRK.B, GOOGL, VOO, BX |
| Q1 2026 | 7 | $4.0M | GLD, BRK.B, KYTX, LXEO, XFOR |
| Q4 2025 | 11 | $4.3M | GLD, BRK.B, SYRE, MIND MEDICINE MINDMED INC, KYTX |
| Q3 2025 | 12 | $22.9M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, ELVN |
| Q2 2025 | 11 | $9.9M | RZLT, GLD, BRK.B, ELVN, MIND MEDICINE MINDMED INC |
| Q1 2025 | 12 | $5.1M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, BCAX |
| Q4 2024 | 15 | $16.6M | XERS, RZLT, SPY, BRK.B, GLD |
| Q3 2024 | 12 | $24.2M | XERS, RZLT, SPY, BRK.B, BCAX |
| Q2 2024 | 12 | $19.7M | XERS, RZLT, SPY, BRK.B, LXEO |
| Q1 2024 | 11 | $17.6M | XERS, RZLT, SPY, BRK.B, KYTX |